02.04.25 -- How Do We Best Meet Future AAV Production Challenges?

Intensified adherent cell culture offers a promising solution to the limitations of traditional suspension culture, with the potential to improve efficiency, reduce costs, and accelerate development.

As developers begin their AAV therapy research, opting for early-phase studies with an experienced CDMO can help mitigate funding challenges and procure material for clinical data generation.

ADCs have emerged as a promising class of targeted cancer therapies. Explore linker-payload design elements, conjugation and characterization of ADCs, and the different bioassays used to screen ADCs.

Delve into the key obstacles encountered in biologics process development, including the complexities of optimizing production processes, ensuring product consistency, and maintaining quality control.

Find out how a strategic partnership with a used equipment dealer can provide guidance through the process of a merger or acquisition of manufacturing facilities and simplify equipment removal and sales.

When it comes to furthering AAV's potential in the wider biopharmaceutical pipeline, partnering with a CDMO that can foment an optimal analytical and manufacturing strategy is crucial.

Despite the growing body of research and scientific knowledge, perhaps the biggest challenge with LNP formulation is the journey into the unknown.

Identify and address potential anti-drug immune responses early in development to streamline your drug’s path to clinical success—start smart and finish fast.